Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.
Saved in:
| Title: | Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials. |
|---|---|
| Authors: | Ingram, John R.1,2 (AUTHOR) ingramjr@cardiff.ac.uk, Fujita, Hideki3 (AUTHOR), Gottlieb, Alice B.4 (AUTHOR), Lev-Tov, Hadar5 (AUTHOR), Prens, Errol2,6 (AUTHOR), Sayed, Christopher J.2,7 (AUTHOR), Shi, Vivian Y.8 (AUTHOR), Szepietowski, Jacek C.2,9,10 (AUTHOR), Takahashi, Kenzo11 (AUTHOR), Frew, John W.12,13,14 (AUTHOR), Lambert, Jérémy15 (AUTHOR), Davis, Leah16 (AUTHOR), Oh, Tae17 (AUTHOR), Rolleri, Robert16 (AUTHOR), Saintmard, Marie-Hélène15 (AUTHOR), Orenstein, Lauren A. V.18 (AUTHOR) |
| Source: | Pain & Therapy. Dec2025, Vol. 14 Issue 6, p1861-1878. 18p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
